Characterization of COVID‐19 disease in pediatric oncology patients: The New York‐New Jersey regional experience
Pediatric Blood & Cancer2020Vol. 68(3), pp. e28843–e28843
Citations Over TimeTop 10% of 2020 papers
P. Pallavi Madhusoodhan, Joanna Pierro, Jordan Musante, D. P. Kothari, Bradley Gampel, Burton Appel, Adam Levy, Adit Tal, Laura Hogan, Archana Sharma, Shari L. Feinberg, Alissa R. Kahn, Ashley Pinchinat, Teena Bhatla, Chana L. Glasser, Prakash Satwani, Elizabeth A. Raetz, Kenan Onel, William L. Carroll
Abstract
In this large multi-institutional cohort, we observed that mortality and morbidity from COVID-19 amongst pediatric oncology patients were low overall, but higher than reported in general pediatrics. Certain subgroups might be at higher risk of severe disease. Delays in cancer care due to SARS-CoV-2 remain a concern.
Related Papers
- → A framework to develop adapted treatment regimens to manage pediatric cancer in low‐ and middle‐income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP)(2017)91 cited
- → PET/CT in Pediatric Oncology(2019)14 cited
- → COVID-19 in pediatric cancer: Where are the brain tumors?(2021)7 cited
- → Availability of Essential Medicines for Pediatric Oncology in Armenia(2017)
- → COVID-19 in pediatric cancer: where are the brain tumors?(2021)